Cell enrichment-free massive ex-vivo expansion of peripheral CD20+ B cells via CD40-CD40L signals in non-human primates

Jung Sik Kim, Nari Byun, Hyunwoo Chung, Hyun Je Kim, Jong Min Kim, Taehoon Chun, Won Woo Lee, Chung Gyu Park

Research output: Contribution to journalArticle

Abstract

Non-human primates (NHPs) are valuable as preclinical resources that bridge the gap between basic science and clinical application. B cells from NHPs have been utilized for the development of B-cell targeted drugs and cell-based therapeutic modalities; however, few studies on the ex-vivo expansion of monkey B cells have been reported. In this study, we developed a highly efficient ex-vivo expansion protocol for monkey B cells resulting in 99% purity without the requirement for prior cell-enrichment procedures. To this end, monkey peripheral blood mononuclear cells (PBMCs) were stimulated for 12 days with cells constitutively expressing monkey CD40L in expansion medium optimized for specific and massive expansion of B cells. The B cells expansion rates obtained were 2-5 times higher than those previously reported in humans, with rates ranging from 7.9 to 16.6 fold increase. Moreover, expanded B cells sustained high expression of co-stimulatory molecules including CD83 and CD86 until day 12 of culture, and the simple application of a brief centrifugation resulted in a CD20+ B cell purity rate of greater than 99%. Furthermore, small amounts of CD3+CD20+BT-like cells were generated and CD16 was expressed at moderate levels on expanded B cells. Thus, the establishment of this protocol provides a method to produce quantities of homogeneous, mature B cells in numbers sufficient for the in vitro study of B cell immunity as well as for the development of B cell-diagnostic tools and cell-based therapeutic modalities.

Original languageEnglish
Pages (from-to)92-98
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume473
Issue number1
DOIs
Publication statusPublished - 2016 Apr 22

Fingerprint

CD40 Ligand
Primates
B-Lymphocytes
Cells
Haplorhini
Centrifugation
Immunity
Blood Cells
Blood
Cell Count

Keywords

  • B cell
  • CD40-CD40L signals
  • Ex-vivo expansion
  • Monkeys

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Cell enrichment-free massive ex-vivo expansion of peripheral CD20+ B cells via CD40-CD40L signals in non-human primates. / Kim, Jung Sik; Byun, Nari; Chung, Hyunwoo; Kim, Hyun Je; Kim, Jong Min; Chun, Taehoon; Lee, Won Woo; Park, Chung Gyu.

In: Biochemical and Biophysical Research Communications, Vol. 473, No. 1, 22.04.2016, p. 92-98.

Research output: Contribution to journalArticle

Kim, Jung Sik ; Byun, Nari ; Chung, Hyunwoo ; Kim, Hyun Je ; Kim, Jong Min ; Chun, Taehoon ; Lee, Won Woo ; Park, Chung Gyu. / Cell enrichment-free massive ex-vivo expansion of peripheral CD20+ B cells via CD40-CD40L signals in non-human primates. In: Biochemical and Biophysical Research Communications. 2016 ; Vol. 473, No. 1. pp. 92-98.
@article{8ce04764786d4f27aa7ad77e4535d554,
title = "Cell enrichment-free massive ex-vivo expansion of peripheral CD20+ B cells via CD40-CD40L signals in non-human primates",
abstract = "Non-human primates (NHPs) are valuable as preclinical resources that bridge the gap between basic science and clinical application. B cells from NHPs have been utilized for the development of B-cell targeted drugs and cell-based therapeutic modalities; however, few studies on the ex-vivo expansion of monkey B cells have been reported. In this study, we developed a highly efficient ex-vivo expansion protocol for monkey B cells resulting in 99{\%} purity without the requirement for prior cell-enrichment procedures. To this end, monkey peripheral blood mononuclear cells (PBMCs) were stimulated for 12 days with cells constitutively expressing monkey CD40L in expansion medium optimized for specific and massive expansion of B cells. The B cells expansion rates obtained were 2-5 times higher than those previously reported in humans, with rates ranging from 7.9 to 16.6 fold increase. Moreover, expanded B cells sustained high expression of co-stimulatory molecules including CD83 and CD86 until day 12 of culture, and the simple application of a brief centrifugation resulted in a CD20+ B cell purity rate of greater than 99{\%}. Furthermore, small amounts of CD3+CD20+BT-like cells were generated and CD16 was expressed at moderate levels on expanded B cells. Thus, the establishment of this protocol provides a method to produce quantities of homogeneous, mature B cells in numbers sufficient for the in vitro study of B cell immunity as well as for the development of B cell-diagnostic tools and cell-based therapeutic modalities.",
keywords = "B cell, CD40-CD40L signals, Ex-vivo expansion, Monkeys",
author = "Kim, {Jung Sik} and Nari Byun and Hyunwoo Chung and Kim, {Hyun Je} and Kim, {Jong Min} and Taehoon Chun and Lee, {Won Woo} and Park, {Chung Gyu}",
year = "2016",
month = "4",
day = "22",
doi = "10.1016/j.bbrc.2016.03.057",
language = "English",
volume = "473",
pages = "92--98",
journal = "The BMJ",
issn = "0730-6512",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Cell enrichment-free massive ex-vivo expansion of peripheral CD20+ B cells via CD40-CD40L signals in non-human primates

AU - Kim, Jung Sik

AU - Byun, Nari

AU - Chung, Hyunwoo

AU - Kim, Hyun Je

AU - Kim, Jong Min

AU - Chun, Taehoon

AU - Lee, Won Woo

AU - Park, Chung Gyu

PY - 2016/4/22

Y1 - 2016/4/22

N2 - Non-human primates (NHPs) are valuable as preclinical resources that bridge the gap between basic science and clinical application. B cells from NHPs have been utilized for the development of B-cell targeted drugs and cell-based therapeutic modalities; however, few studies on the ex-vivo expansion of monkey B cells have been reported. In this study, we developed a highly efficient ex-vivo expansion protocol for monkey B cells resulting in 99% purity without the requirement for prior cell-enrichment procedures. To this end, monkey peripheral blood mononuclear cells (PBMCs) were stimulated for 12 days with cells constitutively expressing monkey CD40L in expansion medium optimized for specific and massive expansion of B cells. The B cells expansion rates obtained were 2-5 times higher than those previously reported in humans, with rates ranging from 7.9 to 16.6 fold increase. Moreover, expanded B cells sustained high expression of co-stimulatory molecules including CD83 and CD86 until day 12 of culture, and the simple application of a brief centrifugation resulted in a CD20+ B cell purity rate of greater than 99%. Furthermore, small amounts of CD3+CD20+BT-like cells were generated and CD16 was expressed at moderate levels on expanded B cells. Thus, the establishment of this protocol provides a method to produce quantities of homogeneous, mature B cells in numbers sufficient for the in vitro study of B cell immunity as well as for the development of B cell-diagnostic tools and cell-based therapeutic modalities.

AB - Non-human primates (NHPs) are valuable as preclinical resources that bridge the gap between basic science and clinical application. B cells from NHPs have been utilized for the development of B-cell targeted drugs and cell-based therapeutic modalities; however, few studies on the ex-vivo expansion of monkey B cells have been reported. In this study, we developed a highly efficient ex-vivo expansion protocol for monkey B cells resulting in 99% purity without the requirement for prior cell-enrichment procedures. To this end, monkey peripheral blood mononuclear cells (PBMCs) were stimulated for 12 days with cells constitutively expressing monkey CD40L in expansion medium optimized for specific and massive expansion of B cells. The B cells expansion rates obtained were 2-5 times higher than those previously reported in humans, with rates ranging from 7.9 to 16.6 fold increase. Moreover, expanded B cells sustained high expression of co-stimulatory molecules including CD83 and CD86 until day 12 of culture, and the simple application of a brief centrifugation resulted in a CD20+ B cell purity rate of greater than 99%. Furthermore, small amounts of CD3+CD20+BT-like cells were generated and CD16 was expressed at moderate levels on expanded B cells. Thus, the establishment of this protocol provides a method to produce quantities of homogeneous, mature B cells in numbers sufficient for the in vitro study of B cell immunity as well as for the development of B cell-diagnostic tools and cell-based therapeutic modalities.

KW - B cell

KW - CD40-CD40L signals

KW - Ex-vivo expansion

KW - Monkeys

UR - http://www.scopus.com/inward/record.url?scp=84962195816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962195816&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2016.03.057

DO - 10.1016/j.bbrc.2016.03.057

M3 - Article

VL - 473

SP - 92

EP - 98

JO - The BMJ

JF - The BMJ

SN - 0730-6512

IS - 1

ER -